title: Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody.
abstract: CD81 is a required receptor for hepatitis C virus (HCV) infection of human hepatocytes in vitro. We generated several high-affinity anti-human CD81 monoclonal antibodies (mAbs) that demonstrated potent, specific, and cross-genotype inhibition of HCV entry. One of these mAbs, K04, was administered to human liver chimeric mice before or after HCV infection to determine its ability to prevent HCV infection or spread of HCV infection, respectively. All vehicle control mice established HCV infection, reaching steady-state levels of serum HCV RNA by day 21. Pretreatment of mice with K04 prevented HCV infection in all mice (n = 5). Treatment of mice with mAb K04 every 3 days for 21 days, starting at 6 hours postinfection, resulted in effective inhibition of virus spread. In 3 mice that were sacrificed on day 24, serum HCV levels remained detectable, below the limit of quantification (LOQ), indicating that infection was established, but virus spread was blocked, by the anti-CD81 mAb. In 5 additional mice that were followed for a longer time, virus remained detectable, below LOQ, until days 24 and 30 in 4 of 5 mice. In the fifth mouse, viral load was quantifiable, but reduced to 64-fold below the mean viral load in vehicle control at day 24. In addition, 2 of 5 mice cleared the infection by day 30 and 1 mouse had undetectable virus load from day 6 onward.
  
  
  CONCLUSIONS
  These results demonstrate that CD81 is required for HCV infection and virus spread in vivo, and that anti-CD81 antibodies such as K04 may have potential as broad-spectrum antiviral agents for prevention and treatment of HCV infection.
authors.affiliation: Hoffmann-La Roche Inc., Nutley, NJ.
authors.forename: Changhua
authors.initials: C
authors.lastname: Ji
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Chandra
authors.initials: C
authors.lastname: Pamulapati
authors.forename: Sandhya
authors.initials: S
authors.lastname: Bohini
authors.forename: Georg
authors.initials: G
authors.lastname: Fertig
authors.forename: Michael
authors.initials: M
authors.lastname: Schraeml
authors.forename: Werner
authors.initials: W
authors.lastname: Rubas
authors.forename: Michael
authors.initials: M
authors.lastname: Brandt
authors.forename: Stefan
authors.initials: S
authors.lastname: Ries
authors.forename: Han
authors.initials: H
authors.lastname: Ma
authors.forename: Klaus
authors.initials: K
authors.lastname: Klumpp
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002678:Chimera; D006526:Hepatitis C / Q000517:prevention & control*; D006801:Humans; D008099:Liver / Q000821:virology; D051379:Mice; D016513:Mice, SCID; D060225:Tetraspanin 28 / Q000276:immunology*; D019562:Viral Load
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D060225:Tetraspanin 28